• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/13/24 1:31:16 PM ET
    $AIH
    $ANNX
    $COCH
    $CRDF
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    Gainers

    • Heron Therapeutics (NASDAQ:HRTX) shares rose 35.4% to $3.19 during Wednesday's regular session. The market value of their outstanding shares is at $479.4 million. The company's, Q4 earnings came out yesterday.
    • TRACON Pharma (NASDAQ:TCON) stock rose 34.56% to $0.52. The market value of their outstanding shares is at $23.8 million.
    • NuCana (NASDAQ:NCNA) stock rose 34.32% to $0.52. The company's market cap stands at $27.2 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 33.01% to $0.11. The market value of their outstanding shares is at $4.3 million.
    • Cardiff Oncology (NASDAQ:CRDF) shares increased by 27.9% to $5.73. The company's market cap stands at $256.0 million.
    • Annexon (NASDAQ:ANNX) shares increased by 26.36% to $5.8. The company's market cap stands at $453.9 million.

    Losers

    • Trxade Health (NASDAQ:MEDS) shares fell 22.6% to $26.24 during Wednesday's regular session. The market value of their outstanding shares is at $31.6 million.
    • Tenon Medical (NASDAQ:TNON) shares fell 22.0% to $1.13. The company's market cap stands at $2.7 million. The company's, Q4 earnings came out yesterday.
    • P3 Health Partners (NASDAQ:PIII) stock declined by 21.49% to $0.8. The market value of their outstanding shares is at $92.2 million.
    • Envoy Medical (NASDAQ:COCH) stock fell 20.4% to $6.05. The company's market cap stands at $118.2 million.
    • Neumora Therapeutics (NASDAQ:NMRA) stock fell 18.28% to $14.18. The company's market cap stands at $2.2 billion. The company's, Q4 earnings came out 4 days ago.
    • Aesthetic Medical Intl (NASDAQ:AIH) stock declined by 16.28% to $0.36. The market value of their outstanding shares is at $17.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $ANNX
    $COCH
    $CRDF

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    2/17/2026Mkt Perform → Outperform
    William Blair
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    Neumora Therapeutics Inc.
    $NMRA
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    Neumora Therapeutics Inc.
    $NMRA
    9/16/2025Neutral → Underweight
    Analyst
    P3 Health Partners Inc.
    $PIII
    8/28/2025$20.00Buy
    Lake Street
    More analyst ratings

    $AIH
    $ANNX
    $COCH
    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Williamson Kevin converted options into 1,041 shares, increasing direct ownership by 2% to 43,593 units (SEC Form 4)

    4 - Tenon Medical, Inc. (0001560293) (Issuer)

    3/5/26 4:37:46 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard sold $32,004 worth of shares (5,894 units at $5.43), decreasing direct ownership by 3% to 180,093 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/4/26 4:30:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neumora Therapeutics upgraded by William Blair

    William Blair upgraded Neumora Therapeutics from Mkt Perform to Outperform

    2/17/26 7:22:19 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $45,360 worth of shares (8,000 units at $5.67), increasing direct ownership by 15% to 62,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    3/12/26 4:31:34 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive employee received an option to purchase 20,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $5.66, which was t

    3/16/26 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

    WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of th

    3/16/26 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for fourth quarter and full year 2025 on Thursday, March 26, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter and Full Year 2025 Earnings Conference Call Date & Time March 26, 2026, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 International 1-412-317-0692 Ask to be joined into t

    3/13/26 8:05:00 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    SEC Filings

    View All

    SEC Form 144 filed by Annexon Inc.

    144 - Annexon, Inc. (0001528115) (Subject)

    3/2/26 4:02:33 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenon Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tenon Medical, Inc. (0001560293) (Filer)

    2/27/26 4:30:25 PM ET
    $TNON
    Medical/Dental Instruments
    Health Care

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    2/27/26 9:11:14 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $ANNX
    $COCH
    $CRDF
    Financials

    Live finance-specific insights

    View All

    Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

    WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of th

    3/16/26 7:00:00 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    P3 Health Partners Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for fourth quarter and full year 2025 on Thursday, March 26, 2026. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter and Full Year 2025 Earnings Conference Call Date & Time March 26, 2026, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 International 1-412-317-0692 Ask to be joined into t

    3/13/26 8:05:00 AM ET
    $PIII
    Medical/Nursing Services
    Health Care

    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

    – ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of He

    2/26/26 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care